A Phase 1, Open-Label, Randomized, 3-Way Crossover Study In Healthy Subjects To Estimate The Pharmacokinetics Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Filibuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Pfizer
- 09 Jul 2009 Planned number of patients changed from 12 to 14 as reported by ClinicalTrials.gov.
- 09 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2009 Planned end date changed from 1 May 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.